Beam Therapeutics Q1 net loss $69.2M; cash $1.2B; pipeline on track for H2 2022

Beam Therapeutics Inc.

2022-Q1 EPS reported -$1.01 revenue$8,432,000

Net loss $69.2M ($1.01 per share) vs $201.6M ($3.35) in Q1 2021 due to prior-year in-process R&D charge.
Cash, equivalents and marketable securities $1.2B as of March 31, 2022 (vs $965.6M at Dec 31, 2021).
R&D expenses $65.4M (excl. $155M Guide Therapeutics acquisition cost in Q1 2021); G&A $19.2M.
BEAM-101 enrollment, BEAM-102 IND, and BEAM-201 IND all on track for second half of 2022.
Initiated AUNT natural history study in sickle cell trait; appointed Manmohan Singh to exec leadership and Anne Marie Woodland as head of regulatory.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.